A stability indicating HPLC method was developed and validated for quantitative determination of agomelatine in plasma and tablet formulation in the presence of degradation products generated from forced degradation studies. An HPLC method was developed to separate the drug from the degradation products using Waters spherisorb Cyano C 18 column (250 x4.6mm, 5μm) and a mobile phase constituted of trifluoroacetic acid buffer and methanol (50:50 % v/v). The wave length of the detection is 230 nm at a flow rate 1mL/min. The validation data showed that the assay is accurate, precise, sensitive, specific and reproducible for the determination of agomelatine in plasma as well as in tablet formulation in the presence of its degradants. The method is linear from 12.5-37.5 μgmL -1 and accuracy of the method was found to be 100.5 -100.9 % for tablets and 97.84 -101.24% for plasma. The proposed method was found to be suitable for quantitative determination and the stability study of the drug in plasma and tablet formulation.
INTRODUCTION
Agomelatine
EXPERIMENTAL

Instrumentation
The HPLC system used was a Water (SCHARLAU) HPLC grade 2650 BATCH 13791903, comprised of degasser, LC-20AT pump, SIL-20 AC auto sampler, column compartment, SPD-20A UV. Detector.Analytical column used for this method is Waters spherisorb Cyano (250X4.6mm, 5μm)PSS830909.
Mobile Phase Preparation
Prepare a mixture of 50% methanol: 50% buffer solution (prepared by addition of 0.5ml trifluoroacetic acid to 1000 ml water and adjust the pH to 2.5 using triethylamine).
Standard Preparation
Standard stock solution was prepared by dissolving 25 mg of agomelatine in sufficient amount of methanol in a 100 mL volumetric flask and diluted up to the mark with methanol, sonnicate for 5 minutes , dilute 10 ml of this solution into 100 ml using the same solvent.
Sample Preparation
10 tablets were grinded and a quantity containing 25 mg agomelatine was transferred into a 100 mL volumetric flask, 70 ml of methanol is added. Sonnicate for 20 minutes, complete to volume with methanol, mix, and pass through a suitable membrane filter 0.45-μm porosity. 10 ml of this solution is diluted into 100 ml using the same solvent.
Chromatographic Conditions
Before the mobile phase was delivered into the system, buffer solution and methanol were filtered through 0.45mm, PVDF membrane filter and degassed using vacuum. The chromatographic conditions used for the analysis were given below. 
Construction of Calibration Graph
Aliquots of the suitable agomelatine standard solutions were transferred into a series of 10-mL volumetric flasks so that the final concentration was in the range of 12.5-37.5μg/mL. Then the flasks were completed to volume with the mobile phase. 20 μL aliquots were injected (triplicate) and eluted with the mobile phase under the optimum chromatographic conditions. A plot of the average peak area versus the final concentration in μg/mL was then constructed to obtain the standard calibration graph. Alternatively, the linear regression equation was derived.
Procedure For Acid Degradation
50.0 mL of 2N HCl was added to 25 mg of agomelatine and reflux for about 5 hours, the solution was allowed to attain room temperature, then neutralized with 2N NaOH. Evaporate under vacuum to dryness. The residue was extracted three times with 30 ml methanol and filtered into 100 mL volumetric flask then the volume was completed to the mark with methanol.
Application Of The Proposed Method to The Analysis of Agomelatine in Inspago 25mg Tablets
Different volumes of solution prepared from tablets containing different concentrations of agomelatine were analyzed as described under Construction of the calibration graph. The concentration of the drug was determined using, either the calibration curve or the corresponding regression equation. The results obtained were compared to those given with the reference method (Patil, et al., 2012).
Application of the proposed method to the analysis of agomelatine in plasma
1 ml of a solution containing different concentrations of agomelatine (25 -55 µg/mL) and the same concentration of internal standard (20 µg/mL) in acetonitrile was mixed with 0.5 ml plasma, vortex for 1 min. and centrifuged at 5000 rpm for10 min. and 20 μl of the clear acetonitrile supernatant was removed and injected directly into the HPLC system as described under Construction of the calibration graph. The concentration of the drug was determined using, either the calibration curve or the corresponding regression equation. The results obtained were compared to those given with the reference method (Patil, et al., 2012).
RESULTS AND DISCUSSION
Optimization of the chromatographic conditions
The primary target in developing this stability indicating HPLC method was to achieve good resolution between agomelatine and its degradants. To achieve the separation of degradation products, stationary phase of spherisorb column and a combination of mobile phase were used. The separation of degradation products and agomelatine was achieved on spherisorbcyano(250X4.6mm, 5μm) column and buffer: methanol (50:50 %/v/v) as a mobile phase. Mobile phase flow rate was maintained at 1.0 mL min -1 and eluent were monitored at 230 nm. A 20 μl of sample was injected using a fixed loop and the total run time was 8 min.
STABILITY INDICATION OF THE METHOD
Agomelatine was reported to be susceptible to acidic and alkaline conditions, but slight degradation was observed in oxidative and thermal conditions. The molecule was found to be stable under water hydrolytic and photolytic conditions. The stability-indicating capability of the proposed method was tested after accelerated acid degradation of agomelatine. Degradation products did not interfere with the intact drug peak either in standard solution (figures 2a,b,c) or in plasma (figures3a,b). These results demonstrated the ability of the proposed method to be used as a stability-indicating HPLC method for the analysis of agomelatine in plasma as well as tablet formulation. 
METHOD VALIDATION
The optimized chromatographic conditions were validated by evaluating linearity,accuracy,precision, limit of detection, limit of quantification,robustness,specificity, and selectivity in accordance with ICH guidelines (ICH, 2003, 2005) . The validation parameters are showen in Table 1 . 
Figure 4: Linearity Curve of Agomelatine
In plasma, solutions were prepared at six concentrations of agomelatine (25, 30, 35, 45, 50 and 55 µg mL -1 ) and 20 µg mL -1 of IS were extracted from plasma and injected in triplicate. Linear regression of concentration Vs peak area ratio resulted in an average coefficient of determination (R 2 ) 0.999. Regression equation is Y= 0.037x + 0.069 ( Figure 5 ). The method was found to be linear as the R² is greater than 0.99.
Figure 5: Linearity Curve of Agomelatine in Plasma
ACCURACY
Accuracy was calculated as the percentage recovery of the known added amount of agomelatine reference substance in the sample solutions using three concentration levels covering the specified range (12.5, 25, 37.5 µg mL -1 for tablets and 25, 35, 45 µg mL -1 for plasma) . The accuracy of the method ranged from 100.5 to 100.9%for tablets, and from 97.84 to 101.24% for plasma indicating that this assay is reliable and accurate as the average recovery % is within the acceptance limit (Tables 2&3). To prove the accuracy of the proposed method, the results of the assay of the studied drug in pure form as well as in plasma and tablet formulation were compared with the results of reference method (Patil, et al., 2012) . The statistical analysis (Miller JN, and Miller JC, 2005) of the results using student's t-test and variance ratio F-test showed no significant differences between them(Tables 4&5). 
PRECISION
The study of method repeatability was conducted by performing six different test preparations from the same batch of Inspago 25 mg tablets. The results shown in Table 6 , indicates that the method is repeatable as the RSD is less than 2 %. The intermediate precision of the method was also evaluated using intraday and inter-day studies. For intraday studies, the drug at three concentrations was injected in triplicate into the HPLC system and for inter-day studies the drug at three concentrations were injected in triplicate into the HPLC system for three days (Table 7) . 
ROBUSTNESS
Robustness of the method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage. To determine the robustness of the developed method, typical variations in some analytical conditions were tested including change of pH and change of column while the other mobile phase components were held constant in chromatographic condition. The RSD was not more than 2% (Table 8) . The results obtained showed that the method is reliable during normal usage and indicating excellent robustness of the proposed method. 
LIMIT OF DETECTION AND LIMIT OF QUANTITATION:
LOD was determined by establishing the minimum level at which the analyte can reliably be detected (signal-to-noise ratio is 3:1) while LOQ was determined by establishing the lowest concentration of analyte that can be determined with acceptable precision and accuracy (signal-to-noise ratio is 10:1). The limits of detection (LOD) and the limits of quantification (LOQ) were calculated according to ICH Q2 (ICH, 2005) using the following equations: LOD = 3.3 Sa ∕ b, LOQ = 10 Sa ∕ b Where Sa = The standard deviation of the intercept of regression line b = Slope of the calibration curve.The results were shown in Table 1 .
SPECIFITY AND SELECTIVITY
Specificity and selectivity are evaluated by standard solutions against the placebo (formula without active substance) then inject the formula to check the separation of active substances from the excipients (lactose, starch -maize, povidone, sodium starch glycollate, stearic acid, magnesium stearate, silica -colloidal anhydrous hypromellose, iron oxide yellow (CI77492), glycerol, macrogol 6000, titanium dioxide (CI77891), shellac, indigo carmine (CI73015) and propylene glycol).Specificity and selectivity was evaluated by preparation of three samples with the same procedure stated in the method description. The 1st sample is placebo (formula without active substance). The 2nd sample is standard solution (active ingredient with solvent only). The 3rd sample is the formula as is with the same solvent. Then inject the three samples to check the separation of active substances from the excipients and the ability of the preparation procedures to give 100% extraction of the active ingredient . The method found to be specific and selective for agomelatine because no interference between the peak corresponding to the active ingredients and any other peak corresponding to any inactive ingredients , and the response of standard sample and formula sample are so closed what means that the preparation procedures give near to100% extraction of the active ingredient (Table 9) . 
STABILITY OF ANALYTICAL SOLUTION
The stability of the standard and sample solutions were tested at regular intervals. The stability of solutions was determined by comparing results of the assay of freshly prepared standard solutions. The differences in area % values were within 2% up to 72hours for both standard and sample. Agomelatine stability was studied during sample collection, storage and preparation. All stability investigations were conducted using freshly prepared stock solutions in the mobile phase, as well as in the plasma matrix. Stability experiments have extended throughout the analysis duration and until the last test sample was assayed (Tables 10&11). 
CONCLUSION
Forced degradation study on agomelatine in plasma and tablet formulation was carried out under the conditions of acid hydrolysis.Based on the information generated by forced degradation, a stability-indicating assay method was developed and validated. The method was found sufficiently linear, precise, accurate, sensitive and specific to the drug. Study of various robustness parameters revealed the method to be robust. The resolution of drug and degradation products remained unaffected by change in analytical instrument.
